These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 2100182

  • 1. No lens changes caused by simvastatin results from a prospective drug safety study.
    Schmidt J, Schmitt C, Hockwin O.
    Lens Eye Toxic Res; 1990; 7(3-4):643-50. PubMed ID: 2100182
    [Abstract] [Full Text] [Related]

  • 2. Ocular drug-safety study with the HMG-CoA reductase inhibitor pravastatin.
    Schmitt C, Schmidt J, Hockwin O.
    Lens Eye Toxic Res; 1990; 7(3-4):631-42. PubMed ID: 2129220
    [Abstract] [Full Text] [Related]

  • 3. [The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
    Schmidt J, Schmitt C, Hockwin O.
    Fortschr Ophthalmol; 1991; 88(6):843-5. PubMed ID: 1794817
    [Abstract] [Full Text] [Related]

  • 4. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Clinical results of a 3-year follow-up.
    Behrens-Baumann W, Thiery J, Wieland E, Fieseler HG, Seidel D.
    Arzneimittelforschung; 1992 Aug; 42(8):1023-4. PubMed ID: 1418074
    [Abstract] [Full Text] [Related]

  • 5. Ocular drug safety and HMG-CoA-reductase inhibitors.
    Schmidt J, Schmitt C, Hockwin O, Paulus U, von Bergmann K.
    Ophthalmic Res; 1994 Aug; 26(6):352-60. PubMed ID: 7715916
    [Abstract] [Full Text] [Related]

  • 6. [Effectiveness and tolerability of simvastatin in patients with moderate-to-severe hypercholesterolemia. Results of a 12-month study].
    Ghizzoni G, Rusconi C, Faggiano P, Sabatini T, Oneglia C, Gardini A.
    Minerva Cardioangiol; 1993 Mar; 41(3):105-9. PubMed ID: 8510811
    [Abstract] [Full Text] [Related]

  • 7. [Absence of cataractogenic effect of lovastatin (Mevinacor) so far].
    Ulbig M, Schneider T.
    Fortschr Ophthalmol; 1991 Mar; 88(5):431-3. PubMed ID: 1757025
    [Abstract] [Full Text] [Related]

  • 8. Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.
    Behrens-Baumann W, Morawietz A, Thiery J, Creutzfeldt C, Seidel D.
    Lens Eye Toxic Res; 1989 Mar; 6(1-2):331-7. PubMed ID: 2488025
    [Abstract] [Full Text] [Related]

  • 9. [Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up].
    Wenke K, Thiery J, Meiser B, Arndtz N, Seidel D, Reichart B.
    Z Kardiol; 1995 Feb; 84(2):130-6. PubMed ID: 7717016
    [Abstract] [Full Text] [Related]

  • 10. [Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia].
    Darioli R, Bovet P, Brunner HR, Bercher L.
    Schweiz Med Wochenschr; 1990 Jan 27; 120(4):85-91. PubMed ID: 2305221
    [Abstract] [Full Text] [Related]

  • 11. [Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis].
    Giannini SD, de Góes JM, Dereviack BE, Machado C, Forti N, Diament J.
    Arq Bras Cardiol; 1990 Jun 27; 54(6):407-14. PubMed ID: 2288531
    [Abstract] [Full Text] [Related]

  • 12. [Efficacy and safety of simvastatin, a new cholesterol-lowering drug].
    Mol MJ, Stuyt PM, Stalenhoef AF.
    Ned Tijdschr Geneeskd; 1989 Feb 18; 133(7):362-6. PubMed ID: 2927555
    [Abstract] [Full Text] [Related]

  • 13. [Effects of simvastatin on plasma levels of lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia].
    Caruzzo C, Uslenghi E, Varbella F, Caruzzo E, Marcolongo M, Brusca A.
    Minerva Cardioangiol; 1989 Dec 18; 37(12):509-15. PubMed ID: 2695857
    [Abstract] [Full Text] [Related]

  • 14. Lens changes in matched normals and hyperlipidemic patients treated with simvastatin for 2 years.
    Lundh BL, Nilsson SE.
    Acta Ophthalmol (Copenh); 1990 Dec 18; 68(6):658-60. PubMed ID: 2080693
    [Abstract] [Full Text] [Related]

  • 15. [Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
    Riesen WF, Keller U, Del Bufalo A, Reutter FW, Baur HR, Golay A, Bertel O, Kummer H, Kistler H, Ammann F.
    Schweiz Med Wochenschr; 1989 Dec 02; 119(48):1719-23. PubMed ID: 2694363
    [Abstract] [Full Text] [Related]

  • 16. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
    Park S, Kang HJ, Rim SJ, Ha JW, Oh BH, Chung N, Cho SY.
    Clin Ther; 2005 Jul 02; 27(7):1074-82. PubMed ID: 16154486
    [Abstract] [Full Text] [Related]

  • 17. The human lens after 48 weeks of treatment with lovastatin.
    Laties AM, Keates EU, Taylor HR, Chremos AN, Shear CL, Lippa EA, Gould AL, Hurley DP.
    N Engl J Med; 1990 Sep 06; 323(10):683-4. PubMed ID: 2385275
    [No Abstract] [Full Text] [Related]

  • 18. [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
    Berioli S, Bentivoglio M, Conti R, Osanna RA, Savino K, Zollino L, Corea L.
    Cardiologia; 1990 Apr 06; 35(4):335-40. PubMed ID: 2245435
    [Abstract] [Full Text] [Related]

  • 19. Lupuslike syndrome associated with simvastatin.
    Bannwarth B, Miremont G, Papapietro PM.
    Arch Intern Med; 1992 May 06; 152(5):1093. PubMed ID: 1510761
    [No Abstract] [Full Text] [Related]

  • 20. [Hypercholesterolemia in the aged: rational approach to the problem].
    Antonicelli R, Lipponi G, Cadeddu G, Gaetti R.
    Clin Ter; 1992 May 06; 134(3-4):173-80. PubMed ID: 2147617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.